Does Pecs II Block Reduce the Incidence of Post Mastectomy Pain Syndrome (PMPS)? A Cross Sectional Study
NCT ID: NCT04095897
Last Updated: 2019-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
288 participants
OBSERVATIONAL
2018-03-06
2019-02-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Interpectoral-Pectoserratus Plane Block After Breast Cancer Surgery
NCT05568589
Acute & Chronic Post-mastectomy Pain: Can PECS Block Alter the Geography?
NCT04443894
Anesthetic Efficacy of PECS II Block and Parasternal Block
NCT03016117
Pecs II Block and PaB Could be an Alternative in Breast Surgery
NCT02865265
Evaluating The Efficacy Of Pecs II Blockade Compared To Local Anesthetic Infiltration In Controlling Postoperative Pain In Patients Undergoing Oncologic Breast Surgery Under Opioid Free/Sparing Anesthesia.
NCT06889870
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients who underwent MAC from July 2015 - June 2017 in Hospital Kuala Lumpur (HKL) were recruited. In order to standardize surgical technique and reduce confounding factors, case selection was only limited to unilateral MAC. Other breast cancer surgeries, such as wide local excision, modified radical mastectomy (MRM) and lumpectomy, were excluded. Patients with the following characteristics and problems were excluded from our study - past history of chronic pain and on regular analgesics, chemotherapy or radiotherapy before surgery, surgical complications (such as infection or wound breakdown) or cancer recurrence, history of psychiatric illness, inability to be contacted, inability or unwillingness to participate in the study.
There is currently no standard definition for this chronic pain syndrome. Depending on the definitions applied, patient selection and methods used, the incidence varies. The definition of PMPS used in this study was modified from International Association for the Study of Pain19 (IASP) and other studies.9,20 In our study, PMPS is taken as chronic post surgical pain in the anterior aspect of the thorax, axilla, and/or upper half of the arm beginning after mastectomy, without objective evidence of local abnormality, persisting either continuously or intermittently for more than three months after surgery, and may be associated with allodynia or sensory loss.
Questionnaire used in this study was obtained with permission from Dr Manoj Kumar Karmakar, the author of a previous study on the effect of thoracic paravertebral block (TPVB) on chronic pain post mastectomy.21 It was prepared in both English and Malay versions (Appendix 1) to cater for our local population. The English version was translated to Malay using forward and retrograde translation methods to check the reliability and precision of the words by four independent translators who were bicultural Malay speakers with a good command of English. The translation was further evaluated by a panel of experts in the field of Regional Anesthesia and Pain Management to verify the idiomatic and cross-cultural equivalence to the English version. Seven respondents were then recruited to assess face validity of the questionnaire. Repeat evaluation was done until respondents understood all the questions in the process of content validation. No modification was needed as the first draft of questionnaire was well understood by all respondents. Internal consistency reliability and construct validation was done using Cronbach's alpha, Kaiser-Meyer-Olkin (KMO) test and Bartlett's test of sphericity.22 The KMO value of 0.56 and the significant Bartlett's test of sphericity (P\< 0.001) in this validation was acceptable. Cronbach's alpha was 0.736, indicating good internal consistency.
Personal details, medical history and contact number of all patients who underwent MAC within the specified period were collected from patient's medical records with the permission from the Head of Breast and Endocrine Unit, Department of General Surgery, HKL. Each patient who fulfilled the selection criteria was assigned a study number and grouped into either conventional analgesic therapy (Group A) or Pecs II block (Group B).
All patients included in this study had undergone MAC under GA with regular method of induction and maintenance inhalational anesthesia. Those who received Pecs II block had the procedure done before induction of anesthesia by a team of experienced regional anesthesiologists. Both groups received appropriate doses of opioid and nonsteroidal anti-inflammatory drugs (NSAID) for intraoperative analgesia. Post operatively, all patients received standardized oral analgesics for pain control.
The survey was conducted by a single investigator. Recruited patients were seen in the surgical outpatient clinic to obtain consent and complete the questionnaire. Patients who were not seen in the clinic were contacted by telephone to obtain verbal consent and answer the questionnaire according to the template prepared (Appendix 2). A series of questions related to chronic pain of PMPS were asked as per questionnaire.
Using Krejcie and Morgan formula,24 sample size was calculated based on the incidence of PMPS, which was our primary outcome variable. Published data showed that the incidence of PMPS ranges from 11% to 60%.7-10 With expected incidence of 60%, using 2 proportions sample test, we calculated that a minimum of 95 patients per study group would provide 80% power (α = 0.05).
Data were analyzed using SPSS version 23.0 software. Continuous variables are presented as mean ± standard deviations or median (interquartile range) where appropriate. Categorical data is shown as numbers and percentages. Comparison of continuous data between groups was performed by Student's
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
conventional analgesic therapy
Patient underwent mastectomy with conventional analgesic therapy
No interventions assigned to this group
Pecs II block
Patient underwent mastectomy with conventional analgesic therapy with pre induction Pecs II block
Pecs II Block
Peripheral nerve block - Regional anesthesia : Pectoral Nerve block type 2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pecs II Block
Peripheral nerve block - Regional anesthesia : Pectoral Nerve block type 2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universiti Kebangsaan Malaysia Medical Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
YEOH CHIH NIE, Mmed
Role: PRINCIPAL_INVESTIGATOR
Universiti Kebangsaan Malaysia Medical Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universiti Kebangsaan Malaysia Medical Center
Cheras, Kuala Lumpur, Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NMRR ID: 17-2627-38056
Identifier Type: REGISTRY
Identifier Source: secondary_id
FF-2018-084
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.